Despite the challenges of immunotherapy in glioblastoma, the promising outcomes of bispecific ADCs targeting both B7-H3 and immune checkpoints, such as PD-L1 or PD-1, open new possibilities for overcoming resistance mechanisms. The gene discussed is CD276; the disease is glioblastoma.